Abstract:Maria Chiara Parati, 1 Rebecca Pedersini, 2 Gianluca Perego, 3 Roberto Reduzzi, 4 Tommaso Savio, 4 Mary Cabiddu, 1 Karen Borgonovo, 1 Mara Ghilardi, 1 Andrea Luciani, 1 Fausto Petrelli 1 1 Oncology Unit, Medical Science Department, ASST Bergamo Ovest, Treviglio, BG, Italy; 2 Breast Unit-Medical Oncology, ASST Spedali Civili, Brescia, Italy; 3 Pharmacy Unit, IRCCS San Raffaele Hospital, Milan, Italy; 4 Breast Unit, ASST Bergamo Ovest, Treviglio, BG, Italy Correspondence: Fausto Petrelli, Oncology Unit, Medical Sciences Department, ASST Bergamo Ovest, Piazzale Ospedale 1, Treviglio, 24047, BG, Italy, Tel +390363424420, Fax +390363424380, Email Among pre- and postmenopausal women with hormone receptor-positive (HR+) breast cancer (BC), combinations of an aromatase inhibitor (AI) or fulvestrant with a CDK 4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) have demonstrated improved progression-free survival (PFS) and overall survival (OS) compared to standard single-agent hormone therapy alone as first-line therapy for de novo metastatic disease or relapse during or after adjuvant therapy and no previous therapies in an advanced setting. We here reviewed clinical data about ribociclib in advanced and early BC. Also, we shed light on patient selection and special settings in which medical oncologists urgently await an advance in treatment. Ribociclib was FDA-approved in combination with letrozole based on a Phase III study in which 668 postmenopausal women with HR+, HER2-negative recurrent or metastatic BC were treated with first-line letrozole with or without ribociclib. For patients with metastatic disease at presentation or after a course of AIs, the results of the MONALEESA-3 trial suggest ribociclib's efficacy in combination with fulvestrant, and this combination is FDA-approved for initial- and subsequent-line endocrine therapy for postmenopausal women with metastatic hormone receptor-positive, HER2-negative BC. In adjuvant and neoadjuvant settings, the use of CDK 4/6 inhibitors may be useful to boost outcomes in high-risk patients with HR+ BC, but data contrast with those of a phase III study, which produced positive results. New combinations are being explored in upfront disease (neoadjuvant) or in association with other targeted agents in metastatic disease. Compared to other CDK 4/6 available, ribociclib has a higher incidence of liver function test abnormalities than the other agents and can cause QTc prolongation, and therefore may be prudently avoided in patients with cardiac morbidities or other risk factors for QTc prolongation (drugs, interactions). In these cases, different agents (palbociclib or abemaciclib) may be used. In conclusion, ribociclib with letrozole or with fulvestrant is effective for the entire spectrum of patients with HR+ BC in the advanced setting. Ribociclib has all the characteristics of an innovative drug able to change the clinical practice and most BC patients' prognoses. Keywords: breast cancer, ribociclib, CDK 4/6 inhibitors, review Among pre-and postmenopausal women with hormone receptor-positive (HR+) breast cancer (BC), combinations of an aromatase inhibitor (AI) and fulvestrant with a CDK 4/6 inhibitor (palbociclib, ribociclib [RIBO], or abemaciclib) have demonstrated improved progression-free survival (PFS) and overall survival (OS) compared to standard single-agent hormone therapy alone as first-line therapy for de novo metastatic disease or relapse during or after adjuvant therapy and no previous therapies in advanced setting. Despite only 1 Phase 3 trials with abemaciclib provided positive results in adjuvant setting, CDK 4/6 inhibitors have not been fully employed in early disease. Ribociclib was FDA-approved in combination with letrozole (LET) based on a phase III study in which 668 postmenopausal women with HR+, HER2-negative recurrent or metastatic BC were treated with first-line L with and without RIBO. 1 For patients with metastatic disease at presentation or after a course of AIs, the results of the MONALEESA-3 2 trial suggest RIBO's efficacy in combination with fulvestrant, and this combination is FDA-approved for initial- or subsequent-line endocrine therapy (ET) for postmenopausal women with metastatic HR+, HER2-negative BC. In adjuvant and neoadjuvant settings, CDK 4/6 inhibitors may be useful to boost outcomes in high-risk patients with HR+ BC, but data contrast with those from a phase III study, which produced positive results. New combinations are being explored in upfront disease (neoadjuvant) and in association with other targeted agents in metastatic disease. Ribociclib has all the characteristics of an innovative drug that can change the clinical practice and most BC patient -Abstract Truncated-

First line combination of ribociclib and letrozole in patients (pts) with metastatic breast cancer (MBC): Focus on hepatic toxicity in the context of a real–world setting the Italian, multicenter Hermione–8 study.

First-line CDK4/6 inhibitor-based combinations for HR+/HER2-advanced breast cancer: A Bayesian network meta-analysis

Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country

First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

Concurrent use of Radiotherapy and Ribociclib: Preliminary Results and Review of the Literature

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Concurrent use of Radiotherapy and Ribociclib

Palbociclib Plus Letrozole As First-Line Treatment for ER-positive and HER2-negative Advanced Breast Cancer in Chinese Women: a Phase 1 Study

Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study

Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials

Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR+ MBC) and metastatic ovarian cancer (MOC)

The CDK4/6 inhibitor FCN-437c plus letrozole for the treatment of HR+/HER2advanced breast cancer: Updated results from a phase 1b study.

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

116Tip MONALEESA-7: a Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Ribociclib (LEE011) Combined with Standard First-Line Endocrine Therapy (ET) for the Treatment of Premenopausal Women with HR +, HER2– Advanced Breast Cancer (Abc)

CDK4/6 inhibitors and endocrine therapy in the treatment of metastatic breast cancer: A real-world and propensity score-adjusted comparison

The effect of CDK4/6 inhibitors on the overall survival in patients with advanced HR+/HER2- BC in the entire population and in special clinical subgroups of unfavorable prognosis: A review

Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial